Javascript must be enabled to continue!
Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series
View through CrossRef
Abstract
Background
Oxymetazoline hydrochloride ophthalmic solution (0.1%) is a medication used to treat blepharoptosis. Patients who suffer from blepharoptosis have low-lying eyelids that can hinder their vision. Oxymetazoline hydrochloride ophthalmic solution (0.1%) is prescribed to patients to improve their vision by lifting the upper eyelids. Blepharospasm consists of involuntary, bilateral orbicularis oculi muscle movements that result in twitching and eyelid closure. Botulinum toxin is a treatment used to treat blepharospasm by preventing muscle contraction; but it is not always effective.
Case presentation
The effects of treatment with both oxymetazoline hydrochloride ophthalmic solution (0.1%) and botulinum toxin are assessed in three patients: (1) Patient A, a 58-year-old Filipina woman; (2) patient B, a 62-year-old Korean woman; and (3) patient C, A 57-year-old Vietnamese woman. All patients had been diagnosed with blepharoptosis as well as blepharospasm. Each patient was given an opportunity to complete an optional survey to assess not only the efficacy of oxymetazoline hydrochloride ophthalmic solution (0.1%) together with botulinum toxin but also their perceived stress during the past month.
Conclusions
Administering botulinum toxin for the treatment of blepharospasm in patients A and B yielded the expected results; adding oxymetazoline hydrochloride ophthalmic solution (0.1%), a medical treatment for ptosis, to the treatment regimen yielded an unexpected reduction of blepharospasm. We propose that botulinum toxin and oxymetazoline hydrochloride ophthalmic solution (0.1%) can have a synergistic effect on reducing blepharospasm when used concomitantly. We present three cases in which combined use of botulinum toxin with oxymetazoline hydrochloride ophthalmic solution (0.1%) reduced blepharospasm, and propose possible reasons for such effects. We also discuss previous literature in agreement with the results of our cases.
Springer Science and Business Media LLC
Title: Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series
Description:
Abstract
Background
Oxymetazoline hydrochloride ophthalmic solution (0.
1%) is a medication used to treat blepharoptosis.
Patients who suffer from blepharoptosis have low-lying eyelids that can hinder their vision.
Oxymetazoline hydrochloride ophthalmic solution (0.
1%) is prescribed to patients to improve their vision by lifting the upper eyelids.
Blepharospasm consists of involuntary, bilateral orbicularis oculi muscle movements that result in twitching and eyelid closure.
Botulinum toxin is a treatment used to treat blepharospasm by preventing muscle contraction; but it is not always effective.
Case presentation
The effects of treatment with both oxymetazoline hydrochloride ophthalmic solution (0.
1%) and botulinum toxin are assessed in three patients: (1) Patient A, a 58-year-old Filipina woman; (2) patient B, a 62-year-old Korean woman; and (3) patient C, A 57-year-old Vietnamese woman.
All patients had been diagnosed with blepharoptosis as well as blepharospasm.
Each patient was given an opportunity to complete an optional survey to assess not only the efficacy of oxymetazoline hydrochloride ophthalmic solution (0.
1%) together with botulinum toxin but also their perceived stress during the past month.
Conclusions
Administering botulinum toxin for the treatment of blepharospasm in patients A and B yielded the expected results; adding oxymetazoline hydrochloride ophthalmic solution (0.
1%), a medical treatment for ptosis, to the treatment regimen yielded an unexpected reduction of blepharospasm.
We propose that botulinum toxin and oxymetazoline hydrochloride ophthalmic solution (0.
1%) can have a synergistic effect on reducing blepharospasm when used concomitantly.
We present three cases in which combined use of botulinum toxin with oxymetazoline hydrochloride ophthalmic solution (0.
1%) reduced blepharospasm, and propose possible reasons for such effects.
We also discuss previous literature in agreement with the results of our cases.
Related Results
Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections
Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections
Purpose:
The purpose of this study was to assess blepharospasm patients regarding the effect of botulinum toxin in ocular surface parameters.
...
BOTULINUM TOXIN TYPE A: MULTIFACETED THERAPY FOR NEUROLOGICAL, AUTONOMIC AND OCULAR DISORDERS
BOTULINUM TOXIN TYPE A: MULTIFACETED THERAPY FOR NEUROLOGICAL, AUTONOMIC AND OCULAR DISORDERS
Introduction: Botulinum toxin, a neurotoxin produced by Clostridium botulinum, is an effective form of therapy for treating conditions associated with excessive muscle activity or ...
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Introduction This article reviews the mechanism of action of botulinum toxin and provides an overview of its use in hand disorders relevant to hand therapy such as hyperhidrosis, s...
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Background: While botulinum toxin is widely known for its cosmetic applications, its therapeutic potential in dermatology remains under-recognized by the general public. This study...
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Abstract
Botulinum toxin A is a well-known neurotransmitter inhibitor with a wide range of applications in modern medicine. In recent years, botulinum toxin preparations ha...
Efficacy of EMLA Cream in Pain Reduction during Botulinum Toxin Injections for Facial Dystonias
Efficacy of EMLA Cream in Pain Reduction during Botulinum Toxin Injections for Facial Dystonias
Purpose: To determine the efficacy of EMLA cream (Eutectic Mixture of Local Anesthetics) in pain reduction while injecting botulinum toxin in patients with hemifacial spasm and ble...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Botulinum toxin A and chronic back pain: a randomized, double‐blinded study. (Walter Reed Army Medical Center, Washington, DC) Neurology. 2001;56:1290–1293.
Botulinum toxin A and chronic back pain: a randomized, double‐blinded study. (Walter Reed Army Medical Center, Washington, DC) Neurology. 2001;56:1290–1293.
This study investigated the efficacy of botulinum toxin A in chronic low back pain and associated disabilities. Thirty‐one consecutive patients with chronic low back pain who met t...

